skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Tenofovir-associated bone density loss

Mini-review

(11714) Views  (3594) Full article downloads

Authors: Iwen F Grigsby, Lan Pham, Louis M Mansky, et al

Published Date December 2009 Volume 2010:6 Pages 41 - 47
DOI: http://dx.doi.org/10.2147/TCRM.S8836

Iwen F Grigsby1,2,3,4,5, Lan Pham1,2,4, Louis M Mansky3,4,5, Raj Gopalakrishnan3,4, Kim C Mansky1,2,4

1Division of Orthodontics, 2Department of Developmental and Surgical Sciences, 3Department of Diagnostic and Biological Sciences, 4MinnCResT Program, School of Dentistry, and 5Institute for Molecular virology, Academic Health Center, University of Minnesota, Minneapolis, MN, USA

Abstract: Clinical observations have revealed a strong correlation between loss of bone density in HIV-infected individuals, particularly in conjunction with the antiretroviral drug tenofovir, a nucleotide analog that inhibits HIV reverse transcriptase. The most compelling correlations have been observed in clinical studies involving young children and adolescents. These observations strongly suggest that bone density is being affected during active bone growth and development, implicating a role for tenofovir in bone loss. Here we discuss the literature and potential mechanisms for how tenofovir-associated bone loss may arise, which likely involves perturbation of cellular DNA synthesis and gene expression. Elucidation of the mechanism(s) involved in tenofovir-mediated bone loss will help in developing adjuvant therapies to reduce tenofovir-associated bone density loss.

Keywords: tenofovir, osteoblast, osteoclast, dysfunction, PMPA, renal






 

Other articles by Professor Kim Mansky



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Everolimus-eluting stents: update on current clinical studies
Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease